GI Cancer
Advertisement
The study’s primary end point was objective response rate determined through blinded independent central review.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
This marks the first FDA approval of a radioactive drug for patients 12 years or older with SSTER-positive GEP-NETs.
TOPAZ-1's 3-year follow-up is the longest survival follow-up for a global, randomized phase III trial in this setting.
The prognostic value of the Edmonton Symptom Assessment Scale in patients with gastroesophageal cancer was investigated.
A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm.
Researchers also found statistical significance for the TBR SULpeak of the primary and liver lesions.
Atezolizumab/bevacizumab and lenvatinib have both shown efficacy as first-line treatments for hepatocellular carcinoma.
A personalized therapeutic cancer vaccine may increase patient response to PD-1 inhibitors.
Drs. White and Berman consider how the post hoc analysis of CROSSFIRE elucidates the benefit of ablative therapy with IO.
Drs. White and Berman share insights gained from the CROSSFIRE trial comparing IRE with SBRT in advanced pancreatic cancer.
Immunoscore also showed prognostic benefit in DNA mismatch repair proficient disease.
The study’s primary end points were objective response rate, overall survival, and safety.
Patients with a DpR of ≥30% had a favorable survival time with nivolumab monotherapy as a later-line treatment.
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
For those with a PD-L1 CPS of 5 or higher who received the combination therapy, the median OS was not achieved.
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.